{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:00:13Z","timestamp":1790398813748,"version":"4.1.0"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,6]],"date-time":"2017-05-06T00:00:00Z","timestamp":1494028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative therapy for sickle cell disease (SCD); however, its use is limited by lack of suitable human leukocyte antigen (HLA)-matched donors and decreased application in older patients with significant morbidity. Myeloablative, HLA-identical sibling transplantation in children with SCD offers excellent long-term survival, with overall and event-free survival rates of 95% and 92%, respectively. However, the risk of graft-versus-host-disease, infections, infertility, and other long-term transplant complications, further limits its widespread use. Recent approaches using reduced intensity conditioning (RIC) are associated with lower toxicity, allowing extension of this modality to children and adults with significant morbidity; however, these approaches are also associated with increased risk of graft failure. The optimal RIC regimen that strikes the optimal balance between maximizing the rate of stable engraftment while minimizing transplant-related morbidity and mortality is unknown. Alternative donor transplants, most prominently, partial HLA-mismatched related transplants (haploidentical), are being investigated with promising initial results. This review will discuss long-term results of HLA- matched sibling HSCT for SCD, and recent updates on HLA-matched unrelated donor and unrelated umbilical cord blood HSCT for SCD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2017.05.008","type":"journal-article","created":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T04:02:47Z","timestamp":1497585767000},"page":"259-266","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":75,"title":["Hematopoietic stem cell transplantation for sickle cell disease"],"prefix":"10.4103","volume":"10","author":[{"given":"Adetola A.","family":"Kassim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deva","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.hemonc.2017.05.008_b0005","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1182\/blood-2016-05-716910","article-title":"Survival in adults with sickle cell disease in a high-income setting","volume":"128","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.008_b0010","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJM198606193142501","article-title":"Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial","volume":"314","author":"Gaston","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.05.008_b0015","doi-asserted-by":"crossref","unstructured":"Davies EG, Riddington C, Lottenberg R, Dower N. Pneumococcal vaccines for sickle cell disease. Cochrane Database Sys Rrev; 2004. CD003885.","DOI":"10.1002\/14651858.CD003885.pub2"},{"key":"10.1016\/j.hemonc.2017.05.008_b0020","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jpeds.2008.09.052","article-title":"Trends in pediatric sickle cell disease-related mortality in the United States, 1983\u20132002","volume":"154","author":"Yanni","year":"2009","journal-title":"J Pediatr"},{"key":"10.1016\/j.hemonc.2017.05.008_b0025","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1542\/peds.81.6.749","article-title":"Newborn screening for sickle cell disease: effect on mortality","volume":"81","author":"Vichinsky","year":"1988","journal-title":"Pediatrics"},{"key":"10.1016\/j.hemonc.2017.05.008_b0030","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/01.STR.23.8.1073","article-title":"Transcranial Doppler correlation with cerebral angiography in sickle cell disease","volume":"23","author":"Adams","year":"1992","journal-title":"Stroke"},{"key":"10.1016\/j.hemonc.2017.05.008_b0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM199807023390102","article-title":"Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography","volume":"339","author":"Adams","year":"1998","journal-title":"N Eng J Med"},{"key":"10.1016\/j.hemonc.2017.05.008_b0040","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/blood-2010-06-293514","article-title":"Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort","volume":"117","author":"Bernaudin","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.008_b0045","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1401731","article-title":"Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia","volume":"371","author":"DeBaun","year":"2014","journal-title":"New Engl J Med"},{"key":"10.1016\/j.hemonc.2017.05.008_b0050","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1182\/blood-2003-11-3758","article-title":"Survival of children with sickle cell disease","volume":"103","author":"Quinn","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.008_b0055","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3324\/haematol.10937","article-title":"Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London","volume":"92","author":"Telfer","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.hemonc.2017.05.008_b0060","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2009-07-233700","article-title":"Improved survival of children and adolescents with sickle cell disease","volume":"115","author":"Quinn","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.008_b0065","first-page":"445","article-title":"Sickle cell anemia: study of the pediatric mortality in Ile de France from 1985 to 1992","volume":"3","author":"Thomas","year":"1996","journal-title":"Archives Pediatrie Organe officiel Soc francaise pediatrie"},{"key":"10.1016\/j.hemonc.2017.05.008_b0070","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1034\/j.1600-0609.2000.90210.x","article-title":"Acute clinical events in 299 homozygous sickle cell patients living in France. French study group on sickle cell disease","volume":"65","author":"Neonato","year":"2000","journal-title":"Euro J Haematol"},{"key":"10.1016\/j.hemonc.2017.05.008_b0075","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease Life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"New Engl J Med"},{"key":"10.1016\/j.hemonc.2017.05.008_b0080","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM200006223422502","article-title":"Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group","volume":"342","author":"Vichinsky","year":"2000","journal-title":"New Engl J Med"},{"key":"10.1016\/j.hemonc.2017.05.008_b0085","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia","volume":"332","author":"Charache","year":"1995","journal-title":"New Engl J Med"},{"key":"10.1016\/j.hemonc.2017.05.008_b0090","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2009-05-221333","article-title":"The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)","volume":"115","author":"Voskaridou","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.008_b0095","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/bjh.12323","article-title":"The effect of hydroxcarbamide therapy on survival of children with sickle cell disease","volume":"161","author":"Lobo","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2017.05.008_b0100","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/pbc.25608","article-title":"Survival among children and adults with sickle cell disease in Belgium: benefit from hydroxyurea treatment","volume":"62","author":"Le","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.hemonc.2017.05.008_b0105","first-page":"288","article-title":"Cerebrovascular accidents in sickle cell disease: rates and risk factors","volume":"91","author":"Ohene-Frempong","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.008_b0110","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1744-8603-6-2","article-title":"Psychosocial impact of sickle cell disorder: perspectives from a Nigerian setting","volume":"6","author":"Anie","year":"2010","journal-title":"Global Health"},{"key":"10.1016\/j.hemonc.2017.05.008_b0115","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1212\/WNL.56.8.1109","article-title":"Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease","volume":"56","author":"Schatz","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.hemonc.2017.05.008_b0120","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1542\/peds.97.6.864","article-title":"Cognitive functioning and brain magnetic resonance imaging in children with sickle Cell disease. Neuropsychology Committee of the Cooperative Study of Sickle Cell Disease","volume":"97","author":"Armstrong","year":"1996","journal-title":"Pediatrics"},{"key":"10.1016\/j.hemonc.2017.05.008_b0125","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7326\/0003-4819-115-8-614","article-title":"Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality","volume":"115","author":"Powars","year":"1991","journal-title":"Ann Int Med"},{"key":"10.1016\/j.hemonc.2017.05.008_b0130","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bjh.12024","article-title":"High 1 year mortality in adults with sickle cell disease and end-stage renal disease","volume":"159","author":"McClellan","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2017.05.008_b0135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1148\/radiology.187.1.8451435","article-title":"Acute chest syndrome in sickle cell disease: CT evidence of microvascular occlusion","volume":"187","author":"Bhalla","year":"1993","journal-title":"Radiology"},{"key":"10.1016\/j.hemonc.2017.05.008_b0140","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1182\/blood-2002-03-0948","article-title":"Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival","volume":"101","author":"Castro","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.008_b0145","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1182\/blood.V99.11.3999","article-title":"Microvascular abnormalities in sickle cell disease: a computer-assisted intravital microscopy study","volume":"99","author":"Cheung","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.008_b0150","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJMc1411133","article-title":"Transfusions for silent cerebral infarcts in sickle cell anemia","volume":"371","author":"van der Land","year":"2014","journal-title":"New Engl J Med"},{"key":"10.1016\/j.hemonc.2017.05.008_b0155","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(15)01041-7","article-title":"Hydroxycarbamide versus chronic transfusion for maintenance of transcranial Doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, noninferiority trial","volume":"387","author":"Ware","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.hemonc.2017.05.008_b0160","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1182\/blood-2011-11-392340","article-title":"Stroke with transfusions changing to hydroxyurea (SWiTCH)","volume":"119","author":"Ware","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.008_b0165","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2010-01-261123","article-title":"Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease","volume":"117","author":"Hulbert","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.008_b0170","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/ajh.23105","article-title":"Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities","volume":"87","author":"Aygun","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hemonc.2017.05.008_b0175","first-page":"21","article-title":"Community survey on blood donation practices in a northern state of Nigeria","volume":"52","author":"Salaudeen","year":"2012","journal-title":"J Prev Med Hyg"},{"key":"10.1016\/j.hemonc.2017.05.008_b0180","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1537-2995.2009.002402.x","article-title":"The risk of transfusion-transmitted infections in subSaharan Africa","volume":"50","author":"Jayaraman","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.hemonc.2017.05.008_b0185","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/003335491312800206","article-title":"Mortality rates and age at death from sickle cell disease: U.S., 1979\u20132005","volume":"128","author":"Lanzkron","year":"2013","journal-title":"Public Health Rep"},{"key":"10.1016\/j.hemonc.2017.05.008_b0190","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.md.0000189089.45003.52","article-title":"Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients","volume":"84","author":"Powars","year":"2005","journal-title":"Medicine"},{"key":"10.1016\/j.hemonc.2017.05.008_b0195","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bbmt.2015.10.017","article-title":"Indications and results of HLA-identical sibling hematopoietic cell transplantation for sickle cell disease","volume":"22","author":"Walters","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.008_b0200","article-title":"Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","author":"Gluckman","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.008_b0205","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.bbmt.2009.10.005","article-title":"Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease","volume":"16","author":"Walters","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.008_b0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bmt.1701291","article-title":"Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium","volume":"22","author":"Vermylen","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.008_b0215","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/ejh.12082","article-title":"Stem cell transplantation after reduced-intensity conditioning for sickle cell disease","volume":"90","author":"Matthes-Martin","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hemonc.2017.05.008_b0220","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-2141.2006.06486.x","article-title":"Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anaemia: results of the multicenter study of haematopoietic cell transplantation for sickle cell anaemia","volume":"136","author":"Eggleston","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2017.05.008_b0225","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1053\/bbmt.2001.v7.pm11787529","article-title":"Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia","volume":"7","author":"Walters","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.008_b0230","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ajh.24183","article-title":"Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies","volume":"90","author":"King","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hemonc.2017.05.008_b0235","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMoa0904971","article-title":"Allogeneic hematopoietic stem-cell transplantation for sickle cell disease","volume":"361","author":"Hsieh","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.05.008_b0240","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2007-03-079665","article-title":"Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease","volume":"110","author":"Bernaudin","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.008_b0245","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O'Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.008_b0250","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.05.008_b0255","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2016-05-715870","article-title":"A trial of unrelated donor marrow transplantation for children with severe sickle cell disease","volume":"128","author":"Shenoy","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.008_b0260","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.bbmt.2011.01.012","article-title":"Umbilical cord blood transplantation for children with thalassemia and sickle cell disease","volume":"17","author":"Ruggeri","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.008_b0265","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.bbmt.2012.01.019","article-title":"Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)","volume":"18","author":"Kamani","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.008_b0270","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2012-07-438408","article-title":"HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease","volume":"120","author":"Bola\u00f1os-Meade","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.008_b0275","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.bbmt.2013.02.010","article-title":"Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease","volume":"19","author":"Dallas","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.008_b0280","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.bbmt.2014.12.007","article-title":"Health-related quality of life after allogeneic hematopoietic stem cell transplantation for sickle cell disease","volume":"21","author":"Bhatia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.008_b0285","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/bmt.2013.188","article-title":"Targeted Busulfan therapy with a steady-state concentration of 600\u2013700ng\/mL in patients with sickle cell disease receiving HLA-identical sibling bone marrow transplant","volume":"49","author":"Maheshwari","year":"2014","journal-title":"Bone Marrow Transp"},{"key":"10.1016\/j.hemonc.2017.05.008_b0290","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.3324\/haematol.2011.047050","article-title":"Family-directed umbilical cord blood banking","volume":"96","author":"Gluckman","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.hemonc.2017.05.008_b0295","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.hoc.2014.08.014","article-title":"Hematopoietic stem cell transplantation for patients with sickle cell disease: progress and future directions","volume":"28","author":"Fitzhugh","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"issue":"Suppl. 2","key":"10.1016\/j.hemonc.2017.05.008_b0300","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1038\/bmt.2015.92","article-title":"HLA-haploidentical blood or marrow transplantation with high-dose, posttransplantation cyclophosphamide","volume":"50","author":"Fuchs","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.008_b0305","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2013.099747","article-title":"Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel","volume":"99","author":"Angelucci","year":"2014","journal-title":"Haematologica"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387617300444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387617300444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/02275670-201710040-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:50:25Z","timestamp":1787838625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02275670-201710040-00017"}},"subtitle":["The changing landscape"],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2017.05.008","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}